MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1007/s12149-026-02169-1

Медицинская библиотека · Annals of nuclear medicine · 2026

Long-term efficacy and safety of peptide receptor radionuclide therapy in Japanese patients with unresectable neuroendocrine tumor: extension of the Japanese phase I and phase I/II study.

Kobayashi Noritoshi, Ono Hiroaki, Okubo Naoki, Akahoshi Keiichi, Kudo Atsushi, Ban Daisuke, Ichikawa Yasushi

СтатьяКлиническое исследование I фазыКлиническое исследование II фазыПеревод в очереди

Аннотация

OBJECTIVE

Peptide receptor radionuclide therapy (PRRT) with radiolabeled somatostatin analogs is an innovative treatment for advanced well-differentiated neuroendocrine tumors (NETs). In Japan, PRRT with Lutetium-177 oxodotreotide (177Lu- oxodotreotide) was recently approved following Phase I and Phase I/II clinical trials, which primarily assessed safety and response rates. However, its long-term efficacy and safety remain unclear. We conducted a record-based analysis of these trials to evaluate progression-free survival (PFS), overall survival (OS), and long-term safety.

METHODS

We recruited Japanese patients from the Phase I and Phase I/II clinical trials. Patients received four infusions of 7.4 GBq 177Lu-oxodotreotide every 8 weeks. We reviewed the database records to assess OS, disease progression, and adverse events.

RESULTS

Twenty-one patients (median age, 57 years) were recruited. The primary tumor sites included the pancreas (n=11), small intestine (n=5), rectum (n=2), lungs (n=2), and stomach (n=1). Twenty (95.2%) patients had liver metastases, whereas 19 (90.5%) had grade 2 tumors. The median PFS period was 36.6 months; median OS period was not reached. Two (9.5%) patients achieved a complete response, 12 (57.1%) achieved a partial response, six (28.6%) had stable disease, and one (4.8%) had progressive disease. One patient had chronic myeloid leukemia 15 months post-PRRT.

CONCLUSIONS

PRRT demonstrated sustained efficacy and safety in Japanese patients with NET.

Для цитирования: Kobayashi Noritoshi, Ono Hiroaki, Okubo Naoki, Akahoshi Keiichi, Kudo Atsushi, Ban Daisuke, Ichikawa Yasushi. Long-term efficacy and safety of peptide receptor radionuclide therapy in Japanese patients with unresectable neuroendocrine tumor: extension of the Japanese phase I and phase I/II study.. Annals of nuclear medicine. 2026. DOI: 10.1007/s12149-026-02169-1.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.